These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 39008362)

  • 1. Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
    Li Y; Li J; Dang Y; Chen Y; Tao C
    JMIR Public Health Surveill; 2024 Jul; 10():e51007. PubMed ID: 39008362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).
    Shin J; Shim SR; Lee J; Ryu HS; Kim JY
    Front Public Health; 2023; 11():1338862. PubMed ID: 38269374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.
    Almadani OA; Alshammari TM
    Saudi Pharm J; 2022 Dec; 30(12):1725-1735. PubMed ID: 36601511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
    Gee J; Marquez P; Su J; Calvert GM; Liu R; Myers T; Nair N; Martin S; Clark T; Markowitz L; Lindsey N; Zhang B; Licata C; Jazwa A; Sotir M; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2021 Feb; 70(8):283-288. PubMed ID: 33630816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
    Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System.
    Zhao H; Souders C; Carmel M; Anger JT
    Urology; 2021 Jul; 153():11-13. PubMed ID: 33864857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adverse events following immunization reported with COVID-19 vaccines in Burkina Faso: Analysis of spontaneous reports].
    Sawadogo R; Ouoba J; Ilboudo D; Tchoumbi E; Lankoandé-Haro S; Fofana S; Sombié I; Samadoulougou S; Kirakoya-Samadoulougou F
    Sante Publique; 2024 Feb; 35(6):149-159. PubMed ID: 38388395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis.
    Santi Laurini G; Montanaro N; Motola D
    Eur J Clin Pharmacol; 2023 May; 79(5):657-661. PubMed ID: 36961579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.
    Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
    Glover C; Deng L; Larter C; Brogan C; Richardson O; Huang YA; Kay E; Macartney K; Wood N
    Commun Dis Intell (2018); 2024 Jun; 48():. PubMed ID: 38926650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017.
    Bonaldo G; Vaccheri A; D'Annibali O; Motola D
    Br J Clin Pharmacol; 2019 Mar; 85(3):634-643. PubMed ID: 30569481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.